OBJECTIVE: @entity5445 ( @entity8142 agonists are available for the treatment of type 2 @entity6 . We assessed the efficacy of exenatide and liraglutide to reach the HbA(1c) target of <7% in @entity1 with type 2 @entity6 . RESEARCH DESIGN AND METHODS: We conducted an electronic search for randomized controlled trials (RCTs) involving @entity5445 agonists through September 2010. RCTs were included if they lasted at least 12 weeks, included 30 @entity1 or more, and reported the proportion of @entity1 reaching the HbA(1c) target of <7%. RESULTS: A total of 25 RCTs reporting 28 comparisons met the selection criteria, which included 9771 study @entity1 evaluated for the primary endpoint, 5083 treated with a @entity5445 agonist and 4688 treated with placebo or a comparator drug. @entity5445 agonists showed a statistically significant reduction in HbA(1c) compared to placebo and the proportion of @entity1 achieving the HbA(1c) goal <7% was 46% for exenatide, 47% for liraglutide, and 63% for exenatide LAR (long-acting release). Moreover, the reduction of the HbA(1c) level and the rate of HbA(1c) goal attainment were higher for both exenatide LAR and liraglutide, as compared to comparator drugs. Higher rates of @entity4053 with exenatide b.i.d. and liraglutide compared to placebo were associated with the concomitant use of a @entity4136 . Exenatide b.i.d. and liraglutide were associated with @entity353 compared to placebo or other antidiabetic drugs. Baseline HbA(1c) was the best predictor for achievement of A1c target (overall weighted R(2) value   =   0.513, p   <   0.001). CONCLUSIONS: A greater proportion of @entity1 with type 2 @entity6 can achieve the HbA(1c) goal <7% with @entity5445 agonists compared to placebo or other antidiabetic drugs; in absolute terms, exenatide LAR was best for the attainment of the HbA(1c) goal.

@entity8142 agonists and HBA1c target of <7% in type 2 XXXX : meta-analysis of randomized controlled trials.

@entity1 :: ('9606', 'Species') :: ['participants', 'patients', 'people'] @entity4136 :: ('CHEBI:26831', 'Chemical') :: ['sulfonylurea'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes'] @entity353 :: ('MESH:D015431', 'Disease') :: ['weight loss'] @entity4053 :: ('MESH:D007003', 'Disease') :: ['hypoglycemia'] @entity8142 :: ('2740', 'Gene') :: ['GLP-1) receptor'] @entity5445 :: ('2641', 'Gene') :: ['Glucagon-like peptide-1', 'GLP-1']
@entity6 :: (MESH:D003920,Disease) :: ['diabetes']
